Published in J Am Soc Nephrol on March 24, 2015
Approach to the Highly Sensitized Kidney Transplant Candidate. Clin J Am Soc Nephrol (2016) 0.89
Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol (2016) 0.78
The Complement System and Antibody-Mediated Transplant Rejection. J Immunol (2015) 0.76
The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies. J Immunol Res (2016) 0.75
The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions. Am J Transplant (2016) 0.75
Dialysis Vintage and Outcomes after Kidney Transplantation: A Retrospective Cohort Study. Clin J Am Soc Nephrol (2016) 0.75
Detection of HLA Antibodies in Organ Transplant Recipients - Triumphs and Challenges of the Solid Phase Bead Assay. Front Immunol (2016) 0.75
Interpreting Anti-HLA Antibody Testing Data: A Practical Guide for Physicians. Transplantation (2016) 0.75
Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine. Can J Kidney Health Dis (2017) 0.75
Immunological risk assessment and human leukocyte antigen antibody testing in kidney transplantation. Indian J Nephrol (2016) 0.75
From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. J Immunol Res (2017) 0.75
Monitoring alloimmune response in kidney transplantation. J Nephrol (2016) 0.75
Successful kidney transplantation across a positive complement-dependent cytotoxicity crossmatch by using C1q assay-directed, bortezomib-assisted desensitization: A case report. Medicine (Baltimore) (2017) 0.75
Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med (2011) 6.72
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant (2013) 2.45
Domino paired kidney donation: a strategy to make best use of live non-directed donation. Lancet (2006) 2.38
De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant (2011) 2.28
Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant (2007) 2.28
De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant (2009) 2.24
Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant (2009) 2.22
Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant (2009) 2.21
Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA (2005) 2.15
Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant (2013) 2.12
Equitable allocation of HLA-compatible kidneys for local pools and minorities. N Engl J Med (1994) 2.12
Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet (2005) 2.02
Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant (2014) 2.00
Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant (2011) 1.91
Summary of FDA antibody-mediated rejection workshop. Am J Transplant (2011) 1.87
Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation (2008) 1.84
Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation (2003) 1.80
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant (2012) 1.78
Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant (2013) 1.77
Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol (2004) 1.68
No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation (2011) 1.67
Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant (2007) 1.60
Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant (2003) 1.58
Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant (2010) 1.56
Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant (2004) 1.54
Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant (2009) 1.52
Determinants of C1q binding in the single antigen bead assay. Transplantation (2014) 1.51
HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies. Mol Immunol (2009) 1.50
Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation (2009) 1.47
De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int (2010) 1.45
Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant (2013) 1.44
C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation (2011) 1.43
"Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation (2008) 1.41
Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation. Transplantation (2010) 1.41
Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant (2006) 1.38
Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant (2013) 1.36
Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol (2005) 1.36
Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol (1999) 1.34
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation (2013) 1.33
Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant (2005) 1.32
Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant (2012) 1.31
Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol (2009) 1.29
De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation (2012) 1.28
Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol (2001) 1.26
Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant (2010) 1.24
HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation (2009) 1.23
Desensitization protocols and their outcome. Clin J Am Soc Nephrol (2011) 1.21
Sensitization and sensitivity: defining the unsensitized patient. Transplantation (2000) 1.21
Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation (2011) 1.19
Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol (2009) 1.19
Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant (2012) 1.18
Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol (1998) 1.18
The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation (2004) 1.17
Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int (2005) 1.17
Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation (1989) 1.16
Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation (2005) 1.14
Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation (2003) 1.14
Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant (2011) 1.14
Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant (2012) 1.13
Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant (2009) 1.11
The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation (2013) 1.11
HLA antibody specification using single-antigen beads--a technical solution for the prozone effect. Transplantation (2011) 1.11
Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol (2009) 1.09
Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant (2006) 1.09
Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation (2013) 1.09
Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int (2012) 1.09
Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol (2009) 1.08
Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant (2012) 1.07
Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant (2007) 1.05
Evolution of HLA antibody detection: technology emulating biology. Immunol Res (2004) 1.05
Calculation of a predictive value for transplantation. Transplantation (1985) 1.05
Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant (2006) 1.03
Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant (2013) 1.03
Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant (2008) 1.03
The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation (2010) 1.03
Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation (2011) 1.02
Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? Hum Immunol (2011) 1.01
Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol (2009) 1.00
Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation (1999) 1.00
Outcome of kidney transplantations performed with preformed donor-specific antibodies of unknown etiology. Am J Transplant (2013) 0.98
Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation (2011) 0.98
Flow cytometry crossmatching in human cadaver kidney transplantation. Transplant Proc (1987) 0.98
Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant (2010) 0.98
Single-center kidney paired donation: the Methodist San Antonio experience. Am J Transplant (2012) 0.97
Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay. Transplantation (2011) 0.97
Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation (2010) 0.95
The complement-mediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera. Int J Immunogenet (2012) 0.95
Contributions and clinical significance of IgM and autoantibodies in highly sensitized renal allograft recipients. Transplantation (1989) 0.95
Solid phase HLA antibody detection technology--challenges in interpretation. Tissue Antigens (2010) 0.95
Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J Immunol (2010) 0.94
Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant (2012) 0.94